Human cytomegalovirus neutralising antibodies and use thereof
The invention relates to neutralizing antibodies and antibody fragments having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for a combination of hCMV proteins UL130 and UL131A, or for a combination of hCMV proteins UL128, UL130 and UL131A. The invention relates also to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis and therapy of disease.
1. An isolated antibody, or an antigen binding fragment thereof, that inhibits hCMV infection, comprising the heavy chain CDR1, CDR2, and CDR3 sequences as set forth in SEQ ID NO: 51, SEQ ID NO: 52, and SEQ ID NO: 53, respectively, and the light chain CDR1, CDR2, and CDR3 sequences as set forth in SEQ ID NO: 54, SEQ ID NO: 55, and SEQ ID NO: 56, respectively.
2. An isolated antibody, or antigen binding fragment thereof, comprising the heavy and light chain variable region amino acid sequence as set forth in SEQ ID NO:63 and 64, respectively.
3. The antibody or fragment of claims 1 or 2 , wherein the antibody is a human antibody, a monoclonal antibody, a human monoclonal antibody, a single chain antibody, Fab, Fab', F(ab') 2 , Fv or scFv.
4. An isolated antibody, or antigen binding fragment thereof, that binds to the same epitope as an antibody comprising the heavy and light chain variable region amino acid sequences as set forth in SEQ ID NO:63 and 64, respectively.
5. An isolated nucleic acid molecule comprising a nucleotide sequence encoding the antibody or fragment of claims 1 , 2 or 4 .
6. The nucleic acid molecule of claim 5 comprising a nucleotide sequence that is at least 95% identical to any one of SEQ ID NOs: 57, 58, 59, 60, 61, 62, 65, or 66.
7. An isolated cell expressing the antibody or fragment of claim 1 , 2 or 4 .
8. A pharmaceutical composition comprising the antibody or fragment of claim 1 , 2 or 4 and a pharmaceutically acceptable diluent or carrier.
9. A pharmaceutical composition comprising the antibody or fragment of claim 1 , 2 or 4 and a second antibody, or antigen binding fragment thereof, which inhibits hCMV infection.
10. A pharmaceutical composition comprising the nucleic acid of claim 5 , and a pharmaceutically acceptable diluent or carrier.
11. The antibody or fragment of claim 1 , 2 or 4 , that is specific for a complex comprising hCMV proteins UL128, UL130 and UL131A and inhibits infection of endothelial cells, retinal cells, or dendritic cells by human cytomegalovirus (hCMV), wherein the concentration of antibody required for 50% inhibition of hCMV is 0.1 μg/ml or less.
12. The antibody or fragment of claim 11 , which binds a conformational epitope formed by the three proteins.
13. The antibody or fragment of claim 11 , wherein the concentration of antibody required for 50% inhibition of hCMV is 0.01 μg/ml or less.
14. The antibody or fragment of claim 11 , wherein the concentration of antibody required for 50% inhibition of hCMV is 0.004 μg/ml or less.